The role of resistin gene polymorphism in Iraqi breast cancer patients

Abstract

Introduction and Aim: Breast cancer is a complex disease and one of the most common cancers among women. Breast cancer is linked to a number of inherited gene alterations which could either initiate breast tumors or be involved in the multistage process of breast cancer development. In this study we aimed to genotype the resistin (RETN) gene linked to breast cancer and determine the effects of RETN single nucleotide polymorphisms (rs3219175, rs34788323) to breast cancer in Iraqi women.
 
 Materials and Methods: This study included 70 (35 malignant and 35 benign) patients with breast cancer and 35 breast-cancer free Iraqi women. Blood samples were collected from all women and subjected to two RETN SNPs (rs3219175, rs34788323) genotyping and determining their allelic frequencies. The serum resistin concentration was determined for each sample. Data was subjected to statistical analysis and p-value determined.
 
 Results: A statistically significant difference for the GA genotype in SNP rs3219175 and TT genotype in SNP (rs34788323) was seen among breast cancer patients, and controls. among Iraqi women. The mean resistin concentration was substantially greater in the malignant group (4,194 ng/ml) compared to the benign group (1,651 ng/ml) and the control group (1,476 ng/ml) (P 0.01). The rs34788323 polymorphism's CC genotype could be associated with higher resistin levels. The blood resistin level was substantially greater in breast cancer patients with the AA genotype (7.710 0.57ng/ml) than in benign (2.340 0.24ng/ml) or control group (2.231 0.15ng/ml), although the difference was not statistically significant, according to rs3219175 SNP results. The incidence of breast cancer was 42.85% higher in the middle age group (40-49 years). The study did show a detrimental relationship between BMI and tumour size, stage, and grade.
 
 Conclusion: Results indicate a correlation between retn gene polymorphism, resistin serum levels and breast cancer susceptibility.